Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
G-PUR is a purified clinoptilolite-tuff (PCT) product, a natural aluminosilicate mineral classified as a zeolite. Its primary mechanism is adsorptive binding in the gastrointestinal tract, where it can sequester substances such as heavy metals (e.g., lead), toxins, and potentially other compounds, thereby reducing their absorption into the body[2][1]. This property is leveraged for its use in gut health, and it has been clinically investigated for the symptomatic treatment of irritable bowel syndrome with diarrhea (IBS-D), with evidence supporting benefits in improving abdominal symptoms, stool consistency, and possibly gut microbiome diversity[1]. It is also touted for its ability to bind dietary cholesterol and toxic heavy metals[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on G-PUR.